Skip to main content
OpenTrials
Completed

NCT Number: NCT05415748

Deprescribing Tamsulosin in Older Men

This is a pilot 12-week randomized, placebo-controlled N-of-1 deprescribing trial among older men receiving chronic tamsulosin therapy for lower urinary tract symptoms attributed to benign prostatic hyperplasia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Benign Prostatic Hyperplasia Genital Diseases Genital Diseases, Male Lower Urinary Tract Symptoms Male Urogenital Diseases Pathological Conditions, Signs and Symptoms Prostatic Diseases Prostatic Hyperplasia Signs and Symptoms Urogenital Diseases Urological Manifestations

Age range

55 year–80 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

University of California, San Francisco

San Francisco, California, 94143, United States

About this study

The investigators will instruct participants to monitor and record their daily urinary symptoms and medication side effects through Redcap surveys, accessible via smartphone. Medication adherence, global urinary satisfaction questions, and health-related quality of life will be assessed as baseline and at the end of the study.

Monitoring frequency: Participants will monitor their symptoms every day using the PERSONAL-pilot study Redcap surveys. If the investigators notice a subject has been unresponsive to daily symptom monitoring, the investigators will reach out to the subject and offer any help we can provide. The investigators first attempt will be in the form of an email, sent to the email address provided to send patients the surveys. If the investigators do not receive a response, the investigators will follow up with a phone call to offer any help or guidance. Email template and telephone script provided in other study documents of the application.

N-of-1 Trial Procedures:

Participants will start with a 1-week open label period where participants will use the PERSONAL Redcap surveys to track daily symptoms and side effects while not taking their tamsulosin or any study pills. Based on the pharmacokinetics and expected timeframe of symptomatic relief from tamsulosin (half-life=14 to 15 hours; steady state by the 5th day of daily dosing), all N-of-1 trials will have a duration of 11 weeks during which participants will complete 2 cycles consisting of a pair of 2-week treatment periods (taking tamsulosin or placebo) separated by 1 week of wash-out on placebo. The order of treatment periods within a cycle will be random (e.g. ABAB, BABA, ABBA, or BAAB) according to pre-filled bubble packs given to participants during their orientation visit.

Participants will receive a placebo during wash-out periods between treatment periods and cycles, but the participants will be unaware of the order or duration of treatment periods or cycles to prevent self-correlating symptoms to specific treatments.

The PERSONAL Redcap will present participants with a daily questionnaire, accessible via smartphone, to track their lower urinary tract symptoms and medication side effects. All participants will also be presented a global urinary symptom bother question. At the end of each week, participants will receive additional medication adherence and treatment satisfaction questionnaires administered via the PERSONAL app as well as motivational messages summarizing their progress in the trial.

Participants will view a graphical representation of their responses summarized in chronological order for the prior day, week, or month. To maximize adherence to daily questionnaires, participants will be contacted via email or phone if they have completed fewer than 4 daily questionnaires in any week during their N-of-1 trial. At the end of the study, the participants will complete an end of-study questionnaire and a 10-30 min. interview with staff member with formal qualitative research training. Then, PERSONAL staff will review N-of-1 trial results with the participant.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Urology patient at UCSF
  • Must own Android or iPhone smartphone, tablet, or computer
  • Taking tamsulosin for urinary-related symptoms
  • Able to speak and read English
  • Male 55-80 years old of age at telephone screening.
  • Written informed consent (and assent when applicable) obtained from subject or subject' s legal representative and ability for subject to comply with the requirements of the study.
  • Willing to receive electronic PERSONAL daily intake surveys for 3 months
  • Willing to self-report urinary symptom or medication side effect data at specified frequency.
  • Have home WiFi access.
  • Patients with h/o prostate cancer may be enrolled but is not required
  • Patients with h/o kidney stones may be enrolled but is not required

Exclusion criteria

  • Taking tamsulosin for <12 months.
  • International Prostate Symptom Score <5 or >25
  • Current participation in any other mobile app-based clinical study.
  • Planning to relocate from area within the study duration.
  • Impaired vision that could limit the use of the mobile apps (participant-reported)

Treatment and study plan

Tamsulosin

Drug

Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks

Other names: Flomax

Placebo

Drug

Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks

Primary outcomes

  1. Change in Adapted International Prostate Symptom Score (IPSS)

    Time frame: Every day for 12 weeks. Daily adapted IPSS scores will be averaged over the treatment period.

    Lower urinary tract symptoms will be measured using the adapted IPSS (recall period changed from 1 month to 24 hours). The score ranges from 0-35, with higher scores indicating more severe symptoms.

Secondary outcomes

  1. Medication Side Effect Scale

    Time frame: Daily for 12 weeks. Daily adapted IPSS scores will be averaged over the treatment period.

    It's a self-reported instrument assessing the presence and severity of common tamsulosin side effects over the past 24 hour period. Possible scores range from 0 (not at all bothered) to 3 (extremely bothered). The total score ranges from 0-36.

Other outcomes

  1. Urinary Bother Scale

    Time frame: Baseline and 12-week follow-up

    It's a self-reported instrument assessing how the participants would feel if they were to spend the rest of their life with their urinary condition as it is now for the past 24 hour period. Possible scores range from 0 (delighted) to 6 (terrible).

  2. PROMIS 29 v2.0

    Time frame: Baseline and 12-week follow-up

    The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain.

  3. Voils Medication Adherence Questionnaire

    Time frame: Baseline and 12-week follow-up

    Participants were asked several questions regarding the extent of medication nonadherence and the reasons for medication nonadherence.

    For the extent of medication nonadherence, 3 questions were asked. Possible scores range from 0 (strongly disagree) to 4 (strongly agree, worse outcome) per question.

    For the reasons of medication nonadherence, 19 questions were asked. Possible scores range from 0 (not at all) to 4 (very much, worse outcome) per question.

  4. Post-Study System Usability Questionnaire

    Time frame: 12-week follow-up

    Participants were asked their perceived satisfaction with the usability of the PERSONAL app. 8 questions were asked. Possible scores range from 0 (strongly disagree) to 4 (strongly agree, better outcome) per question.

  5. Revised Patients' Attitudes Towards Deprescribing (rPATD) Questionnaire

    Time frame: Baseline and 12-week follow-up

    Participants were asked several questions regarding their beliefs and attitudes towards deprescribing.

  6. Perceived Change in Urinary Status Questionnaire

    Time frame: Baseline and 12-week follow-up

    Participants were asked several questions if they felt that their urinary symptoms were unchanged, improved, or worsened

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

PlacEbo-controlled, Randomized, Patient-Selected Outcomes N-of-1 triALs (PERSONAL-pilot): Alpha-blockers for Lower Urinary Tract Symptoms

Acronym: PERSONAL

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jun 13, 2022
Registry last updated
Aug 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.